HOME > BUSINESS > Article

Text Size

small

medium

large


Novartis Fails to Report Over 2,500 Cases of Serious Side Effects

Novartis Fails to Report Over 2,500 Cases of Serious Side Effects

   Tokyo, Aug. 29 (Jiji Press)--Novartis Pharma K.K. said Friday that it has failed to report to the Japanese health ministry at least 2,579 cases of serious side effects, including a fatal case, from its drugs for leukemia and other diseases although employees of the company were aware of the problem.
   Of the total, 1,313 cases were related to Glivec and 514 cases to Tasigna, both drugs for leukemia treatment, and 261 cases involved Afinitor, a drug for cancer, said the Japanese unit Swiss drug giant Novartis AG.

To read a full story, please click here to find out how to subscribe.

BUSINESS

HEADLINES

POLITICS
Indian Prime Min. Modi Voices Willingness to Strengthen Security Ties with Japan
ECONOMY
Japan Govt, Ruling Parties Look at Doubling Size-Based Corporate Tax
SPORTS
Japan Panel Proposes Ambassador for Sports ahead of 2020 Tokyo Olympic Games
OTHER
5,000 Join Central Tokyo Quake Drill Assuming Temblor Directly Hitting Capital

AFP-JIJI PRESS NEWS JOURNAL


Photos